# Progress Note 07 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ada Lovelace (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI031-SYN-TD
- Date: 1851-10-20
- Fictional facility: St. Posthumous Health Center
- Fictional author: Constance Whitley-Adeyemi, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Twenty-week review a week after the sixth and last chemotherapy cycle: blood counts, thyroid on pembrolizumab, tapering morphine, mood and her work. **S**

## History of present illness

Mrs. Lovelace returns a week after her sixth and last cycle of carboplatin and paclitaxel; pembrolizumab continues every three weeks. She has had no bleeding. Her average pain is 2 of 10, and she has used a breakthrough dose only twice in the past month. She would like to take less morphine. The tingling in her toes is unchanged. She feels a little more tired than usual but has no cold intolerance, constipation beyond her usual, weight gain, or palpitations. Her mood is better and she is working on new mathematical notes most mornings. **S**

| Element | Detail |
|---|---|
| Treatment | Six cycles completed; pembrolizumab continues |
| Pain | Average 2 of 10; two breakthrough doses in a month |
| Neuropathy | Mild, unchanged |
| Thyroid symptoms | Slightly more tired; no cold intolerance or weight gain |
| Work | New mathematical notes most mornings |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | A little more tired; weight steady |
| Endocrine | Negative | No cold intolerance, hair or skin change beyond chemotherapy, or palpitations |
| Neurological | Positive | Mild toe tingling, unchanged |
| Psychiatric | Negative | Mood better; PHQ-9 5 |

4 systems reviewed. **S**

## Current medications

- Morphine sulfate oral solution 2 mg/mL, 5 mg (2.5 mL by oral syringe) every 4 hours as needed for pain **S**
- Morphine sulfate extended-release 15 mg tablet, one tablet by mouth at night, for two weeks, then stop **S**
- Naloxone 4 mg nasal spray, one spray in a nostril for suspected opioid overdose; call 911 **S**
- Senna 8.6 mg tablet, two tablets by mouth at night **S**
- Polyethylene glycol 3350, 17 g in water by mouth once or twice a day **S**
- Acetaminophen 500 mg tablet, two tablets by mouth three times a day **S**
- Pembrolizumab 200 mg intravenously every 3 weeks **S**
- Ondansetron 8 mg tablet, one tablet by mouth twice a day for three days after each chemotherapy cycle, then as needed **S**

## Allergies

- No known allergy **S**

## Objective

BP 114/72 mmHg; pulse 78 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 54.4 kg; BMI 20 kg/m². All vital signs are synthetic.

Hemoglobin: 10.9 g/dL (low); White cells: 4.2 10*3/uL; Neutrophils: 2.4 10*3/uL; Platelets: 188 10*3/uL; Creatinine: 0.71 mg/dL; ALT: 24 U/L; TSH: 7.8 mIU/L (high); Free T4: 1 ng/dL; eGFR: 114 mL/min/1.73 m²; Pelvic pain, average over the past week (0 to 10): 2; PHQ-9: 5. All results are synthetic.

## Change since baseline

- Hemoglobin: 8.4 g/dL (low) at baseline, 10.9 g/dL (low) at this visit **S**
- White cells: 7.8 10*3/uL at baseline, 4.2 10*3/uL at this visit **S**
- Platelets: 412 10*3/uL (high) at baseline, 188 10*3/uL at this visit **S**
- Creatinine: 0.68 mg/dL at baseline, 0.71 mg/dL at this visit **S**
- ALT: 18 U/L at baseline, 24 U/L at this visit **S**
- eGFR: 116 mL/min/1.73 m² at baseline, 114 mL/min/1.73 m² at this visit **S**
- Pelvic pain, average over the past week (0 to 10): 7 at baseline, 2 at this visit **S**
- PHQ-9: 8 at baseline, 5 at this visit **S**

## Immunizations given today

- Influenza vaccine, inactivated, trivalent **S**
- COVID-19 mRNA vaccine, current season **S**
- Recombinant zoster vaccine, dose 2 of 2 **S**
- Hepatitis B vaccine, CpG-adjuvanted (two-dose series), dose 2 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well, alert; blood pressure 114/72, pulse 78, weight 54.4 kg |
| Neck | No thyroid enlargement or tenderness |
| Neurological | Reflexes normal; grade 1 sensory neuropathy at the toes |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Metastatic cervical adenocarcinoma, after six cycles; on pembrolizumab** (C53.0). Counts recovering: hemoglobin 10.9 g/dL, white cells 4.2, neutrophils 2.4, platelets 188; creatinine 0.71 mg/dL, ALT 24 U/L. TSH 7.8 mIU/L with a normal free T4 of 1.0 ng/dL: subclinical hypothyroidism, most likely immune-related thyroiditis from pembrolizumab, grade 1; under the ASCO guideline pembrolizumab continues and levothyroxine is not needed unless TSH rises above 10 or symptoms develop. **S**
   - Continue pembrolizumab every 3 weeks.
   - TSH and free T4 in six weeks under the standing order.
   - Restaging CT in about six weeks.
   - Influenza, COVID-19, second zoster and second hepatitis B vaccines today, between cycles.
2. **Cancer-related pelvic pain, well controlled** (G89.3). Average 2 of 10 with almost no breakthrough doses after radiation and the tumor's response; she wants less morphine, and a slow reduction is appropriate. **S**
   - Long-acting morphine 15 mg at night only for two weeks, then stop.
   - Keep oral morphine 5 mg as needed and acetaminophen.
   - Telephone check in one week for any return of pain or withdrawal symptoms.
3. **Long-term opioid therapy, tapering** (Z79.891). Safe use throughout; no signs of use disorder. **S**
   - Keep naloxone at home; return unused morphine to a pharmacy take-back.
4. **Anemia** (D50.0). Hemoglobin 10.9 g/dL after chemotherapy; no bleeding. **S**
   - Blood count with pembrolizumab cycles.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count (hemoglobin, white cells, neutrophils, platelets) | Before each chemotherapy cycle and at each visit | Completed today | Hemoglobin 10.9 g/dL, white cells 4.2, neutrophils 2.4, platelets 188 |
| Laboratory | Creatinine, eGFR and ALT | Before each cycle | Completed today | Creatinine 0.71 mg/dL, eGFR 114, ALT 24 U/L |
| Laboratory | TSH and free T4 on pembrolizumab | Baseline, then every 6 weeks | Completed today | TSH 7.8 mIU/L, free T4 1.0 ng/dL, six weeks after the last check; subclinical; repeat in six weeks |
| Examination | Vaginal bleeding and transfusion need | Every visit | Completed today | No bleeding |
| Examination | Immune-related adverse effects: rash, diarrhea, cough, fatigue | Every visit | Completed today | Mild tiredness only |
| Examination | Peripheral neuropathy on paclitaxel | With taxane treatment and after | Completed today | Grade 1, unchanged |
| Imaging | Restaging CT of chest, abdomen and pelvis | Every 2 to 3 cycles during first-line therapy, then every 3 months | Due | About three months after the last CT, in six weeks |
| Survey | Pain intensity (0 to 10) and function | Every visit | Completed today | Average 2 of 10 |
| Medication safety | Opioid taper when pain improves | When pain is controlled after treatment | Completed today | Long-acting morphine reduced to nightly for two weeks, then stopped |
| Medication safety | Opioid adverse effects: sedation, confusion, nausea | Every visit | Completed today | No sedation |
| Medication safety | Bowel regimen and constipation | Every visit | Completed today | Regular |
| Medication safety | Naloxone, locked storage, one prescriber, prescription monitoring check | At each opioid change | Completed today | Naloxone in date; take-back advised |
| Survey | Depression screen (PHQ-9) and distress | Periodically | Completed today | PHQ-9 5 |
| Referral | Specialist palliative care | Ongoing alongside cancer treatment | Up to date | Monthly palliative care visits |
| Self-management | Goals-of-care conversation | At each restaging | Up to date | Recorded six weeks ago; to revisit after the next CT |

## Goal progress

- Average pelvic pain at or below 3 of 10 without daytime sedation. Outcome by 1851-07-14: Average pain 3 of 10 after radiation, on long-acting morphine, without daytime sleepiness. **S**
- Bleeding controlled and hemoglobin above 10 g/dL without transfusion. Outcome by 1851-09-08: No bleeding since radiation; hemoglobin 10.6 g/dL. **S**
- A documented goals-of-care conversation and a named health care agent. Outcome by 1851-09-08: Advance care plan and goals-of-care conversation recorded. **S**
- Able to work on her mathematics for at least two hours most mornings. Outcome by 1851-10-20: Working most mornings. **S**

## Medication changes

- Stopped: Morphine sulfate extended-release 15 mg tablet, one tablet by mouth every 12 hours; swallow whole **S**
- Started: Morphine sulfate extended-release 15 mg tablet, one tablet by mouth at night, for two weeks, then stop **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer (2026), National Comprehensive Cancer Network
- Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826; Colombo N, et al. N Engl J Med 2021;385:1856-1867) (2021), New England Journal of Medicine
- Palliative Care for Patients With Cancer: ASCO Guideline Update (Sanders JJ, et al. J Clin Oncol 2024;42:2336-2357) (2024), American Society of Clinical Oncology
- Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline (Paice JA, et al. J Clin Oncol 2023;41:914-930) (2023), American Society of Clinical Oncology
- CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022 (Dowell D, et al. MMWR Recomm Rep 2022;71(RR-3):1-95) (2022), Centers for Disease Control and Prevention
- Adult Immunization Schedule by Medical Condition and Other Indication (2026), Centers for Disease Control and Prevention
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (Schneider BJ, et al. J Clin Oncol 2021;39:4073-4126) (2021), American Society of Clinical Oncology

## Follow-up

- Telephone check in one week. Review after the restaging CT in about six weeks. **S**

